Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats.

Antimicrob Agents Chemother · 2017 · PMC5655044 · PMID 28807913

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

There was a nonsignificant trend for improved efficacy against S. aureus with the 1,500-mg oral dose (mean log 10 reduction, 2.4 to 3.1 CFU/abscess).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.